`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`Trademark Trial and Appeal Board
`P.O. Box 1451
`Alexandria, VA 22313-1451
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mailed: June 20, 2008
`
`Opposition No. 91181702
`
`Ther-Rx Corporation
`
`
`
`
`
`v.
`
`TherOx, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`Before Hohein, Rogers and Cataldo, Administrative Trademark
`Judges.
`
`By the Board:
`
`This case now comes up on the following motions:
`
`1) Applicant’s motion to dismiss for failure to state a
`claim or alternative motion to strike, filed February
`15, 2008; and
`
`
`2) Opposer’s motion to amend the notice of opposition,
`filed March 10, 2008.
`
`
`
`
`
`
` We turn first to applicant’s motion to dismiss for
`
`failure to state a claim.
`
`In order to avoid dismissal for failure to state a
`
`claim under Fed.R.Civ.P. 12(b)(6) opposer need only allege
`
`such facts as would, if proved, establish that opposer is
`
`entitled to the relief sought. Therefore, opposer must
`
`allege that (1) it has standing to bring the proceeding, and
`
`(2) a valid ground exists for denying the registration
`
`sought. See TBMP § 503.02 (2d ed. rev. 2004).
`
`
`
`Applicant argues that this proceeding should be
`
`dismissed for failure to plead standing because opposer did
`
`not “claim any common law-rights as a Basis for Opposition”
`
`and opposer is not the owner of the pleaded registration,
`
`Reg. No. 2948813.
`
`
`
`Opposer, while admitting lack of ownership of pleaded
`
`Reg. No. 2948813, argues that its allegation in the first
`
`sentence of paragraph 3 of the notice of opposition is an
`
`assertion of common law rights and “an independent basis”
`
`for standing “sufficient to defeat the Motion to Dismiss.”
`
`
`
`We find that the allegation in paragraph 3 of the
`
`notice of opposition that “Opposer Ther-Rx is the owner of
`
`the mark THER-RX for pharmaceutical products” is a
`
`sufficient allegation of common law rights in the mark THER-
`
`RX, which if proved, would establish opposer’s standing.
`
`
`
`In view thereof, applicant’s motion to dismiss is
`
`denied.
`
`
`
`We turn next to applicant’s alternative motion to
`
`strike and opposer’s motion to amend the notice of
`
`opposition to add a joint opposer.
`
`
`
`Applicant seeks to strike the second sentence of
`
`paragraph 3 of the notice of opposition that “Opposer is
`
`further the owner of U.S. Registration No. 2,948,813 for THE
`
`THER-RX CONTINUUM OF WOMEN’S CARE & Design for ‘supplements;
`
`prenatal nutritional supplements, vitamins and
`
`2
`
`
`
`pharmaceutical and therapeutic substances, oral
`
`contraceptives, anti-infective, electrolytes, fertility
`
`enhancement preparations and agents, anti-inflammatories,
`
`nausea treatment preparations and agents, hormones,
`
`analgesics, migraine treatment preparations, muscle
`
`relaxants, nausea treatment preparations and agents for the
`
`treatment of a wide variety of illnesses, diseases and
`
`medical conditions, namely, neonatal conditions,
`
`osteoporotic conditions, aging, migraines, hypokalemia,
`
`menopause, fungal and microbial infections, virological
`
`infections, infertility, conception, osteoporosis, muscle
`
`pain, hormone replacement therapy, and morning sickness’
`
`(collectively ‘Opposer’s THER-RX Mark’)” since opposer is
`
`not the owner of the registration.
`
`
`
`In response, opposer advises that its pleading of
`
`ownership of Reg. No. 2948813, was an inadvertent mistake
`
`made in good faith and that the “undisputed owner” thereof
`
`is opposer’s “sister company,” DrugTech Corporation.
`
`Opposer seeks to maintain the second sentence of paragraph 3
`
`of the notice of opposition and “to cure Opposer’s
`
`inadvertent misidentification of itself as owner of
`
`Registration no. 2,948,813” by amending the notice of
`
`opposition to add DrugTech Corporation as a joint opposer.
`
`
`
`With regard to opposer’s motion to amend to join
`
`DrugTech Corporation as a party opposer, we note that
`
`3
`
`
`
`joinder is not allowable under these circumstances. Once a
`
`timely notice of opposition has been filed, and the time to
`
`oppose has expired, the right to pursue the filed case is a
`
`right individual to the timely filer. After commencement
`
`of the case, this right to oppose in certain circumstances
`
`may be transferred, but it may not be shared. SDT Inc. v.
`
`Patterson Dental Co., 30 USPQ2d 1707 (TTAB 1994).1 Joinder
`
`in this case would essentially allow DrugTech Corporation to
`
`file an untimely notice of opposition, which is not
`
`permitted. Accordingly, opposer’s motion to amend the
`
`notice of opposition to join DrugTech Corporation as party
`
`opposer is denied.
`
`
`
`With regard to applicant’s motion to strike, we agree
`
`that the second sentence in paragraph 3 of the notice of
`
`opposition should be stricken inasmuch as opposer is not the
`
`owner of Reg. No. 2948813. In view thereof, applicant’s
`
`motion to strike is granted and the second sentence in
`
`paragraph 3 of the notice of opposition is hereby stricken.
`
`
`
`In summary, applicant’s motion to dismiss and opposer’s
`
`motion to amend are denied and applicant’s motion to strike
`
`is granted.
`
`
`1 Prior to commencement of an opposition, a party in privity with
`a potential opposer who has obtained an extension of time to
`oppose may join with the potential opposer and seek further
`extensions or join with the opposer in filing the opposition.
`Such circumstances are not presented by this proceeding.
`Further, sister corporations are not generally held to be in a
`
`4
`
`
`
`
`
`Proceedings are resumed.
`
`We note that applicant has already filed its answer.
`
`The discovery conference, disclosures, discovery and trial
`
`dates are reset as follows:
`
`Deadline for Discovery Conference
`Discovery Opens
`Initial Disclosures Due
`Expert Disclosures Due
`Discovery Closes
`Plaintiff's Pretrial Disclosures
`Plaintiff's 30-day Trial Period Ends
`Defendant's Pretrial Disclosures
`Defendant's 30-day Trial Period Ends
`Plaintiff's Rebuttal Disclosures
`Plaintiff's 15-day Rebuttal Period Ends
`
`
`
`7/18/08
`7/18/08
`8/17/08
`12/15/08
`1/14/09
`2/28/09
`4/14/09
`4/29/09
`6/13/09
`6/28/09
`7/28/09
`
`In each instance, a copy of the transcript of testimony
`
`together with copies of documentary exhibits, must be served
`
`on the adverse party within thirty days after completion of
`
`the taking of testimony. Trademark Rule 2.l25.
`
`Briefs shall be filed in accordance with Trademark
`
`Rules 2.128(a) and (b). An oral hearing will be set only
`
`upon request filed as provided by Trademark Rule 2.l29.
`
`
`
`
`
`
`
`
`
`
`
`* * * *
`
`The USPTO published a notice of final rulemaking in the
`Federal Register on August 1, 2007, at 72 F.R. 42242. By
`this notice, various rules governing Trademark Trial and
`Appeal Board inter partes proceedings are amended. Certain
`amendments have an effective date of August 31, 2007, while
`most have an effective date of November 1, 2007. For
`further information, the parties are referred to a reprint
`of the final rule and a chart summarizing the affected
`rules, their changes, and effective dates, both viewable on
`the USPTO website via these web addresses:
`
`privity relationship, as are parent and subsidiary or assignor
`and assignee.
`
`
`5
`
`
`
`http://www.uspto.gov/web/offices/com/sol/notices/72fr42242.pdf
`http://www.uspto.gov/web/offices/com/sol/notices/72fr42242_FinalRuleChart.pdf
`
`By one rule change effective August 31, 2007, the Board's
`standard protective order is made applicable to all TTAB
`inter partes cases, whether already pending or commenced on
`or after that date. However, as explained in the final rule
`and chart, this change will not affect any case in which any
`protective order has already been approved or imposed by the
`Board. Further, as explained in the final rule, parties are
`free to agree to a substitute protective order or to
`supplement or amend the standard order even after August 31,
`2007, subject to Board approval. The standard protective
`order can be viewed using the following web address:
`http://www.uspto.gov/web/offices/dcom/ttab/tbmp/stndagmnt.htm
`
`
`6